Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 3140983, 12 pages
Review Article

Liver Illness and Psoriatic Patients

1Department of Anaesthesiological, Surgical and Emergency Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
2Department of Medicine, Division of Infectious Diseases, “San Giuseppe Moscati” Hospital, Avellino, Italy
3Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
4Department of Pathophysiology and Transplantation, Dermatology Unit, IRCCS Ca' Granda, University of Milan, Milan, Italy
5Study Center of Young Dermatologists Italian Network (YDIN), Bergamo, Italy

Correspondence should be addressed to Marco Fiore; ti.liamtoh@eroif.ocram and Sebastiano Leone; ti.oohay@enoelonaitsabes

Received 31 August 2017; Revised 30 October 2017; Accepted 4 January 2018; Published 6 February 2018

Academic Editor: Dimitrios P. Bogdanos

Copyright © 2018 Marco Fiore et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world’s population. Systemic treatments, including methotrexate and cyclosporin, are associated with potential hepatotoxicity, due to either direct liver damage or immunosuppression or both immunomediated and a direct liver injury; therefore, treatment of patients with psoriasis poses a therapeutic challenge. The aim of this minireview is to help clinicians in the management of psoriatic patients who develop signs of liver dysfunction. To find relevant articles, a comprehensive search was performed on PubMed, EMBASE, and Cochrane with appropriate combinations of the following keywords being considered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis, hepatotoxicity, drug toxicity, cholestasis, and autoimmune liver diseases.